Compare · BAX vs GUTS
BAX vs GUTS
Side-by-side comparison of Baxter International Inc. (BAX) and Fractyl Health Inc. (GUTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and GUTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BAX is the larger of the two at $9.35B, about 95.1x GUTS ($98.4M).
- Over the past year, BAX is down 40.5% and GUTS is down 48.5% - BAX leads by 8.0 points.
- BAX has been more active in the news (5 items in the past 4 weeks vs 2 for GUTS).
- BAX has more recent analyst coverage (25 ratings vs 6 for GUTS).
- Company
- Baxter International Inc.
- Fractyl Health Inc.
- Price
- $18.15-1.44%
- $0.62+6.99%
- Market cap
- $9.35B
- $98.4M
- 1M return
- +5.95%
- +26.68%
- 1Y return
- -40.53%
- -48.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 6
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Latest BAX
- Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
- SEC Form 3 filed by new insider Foster Julie
- SEC Form 3 filed by new insider Wallace Steven P.
- SEC Form 3 filed by new insider Teaff James
- Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
- Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
- Baxter to Host Annual Meeting of Stockholders in Virtual Format
- Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
- SEC Form DEFA14A filed by Baxter International Inc.
- SEC Form DEF 14A filed by Baxter International Inc.
Latest GUTS
- SEC Form DEFA14A filed by Fractyl Health Inc.
- SEC Form DEF 14A filed by Fractyl Health Inc.
- SEC Form 10-K filed by Fractyl Health Inc.
- Fractyl Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
- Fractyl Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
- Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
- Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.